6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6413974B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 9, 1999 |
| Grant date | Jul 2, 2002 |
| Priority date | — |
| Expiry date | Feb 9, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D473/16
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides novel compounds of the formula (I) whereinR is selected from the group consisting of R2, R2NH—, or H2N—R3— whereinR2 is selected from the group consisting of C1-C8 alkyl and  whereinZ is selected from the group consisting of phenyl, heterocycle and cycloalkyl, each R4 is independently hydrogen or C1-C4 alkyl, and n is an integer 1-8;wherein each C1-C8 alkyl and Z is optionally substituted with 1 to 3 substituents, which may be the same or different, selected from the group consisting of Ha1, OH, and C1-C4 alkyl;R3 is C1-C8 alkylene; andR1 is selected from the group consisting of cyclopentyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof.In addition, the present invention provides a method of inhibiting cell cycle progression. More specifically, the present invention provides a method of inhibiting cyclin dependent kinases, particularly cdk-2.The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.In addition, the present invention provides a composition comprising an assayable amount of a compo…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.